Establishment Labs Holdings Inc (ESTA)
NASDAQ:ESTA
Want to see ESTA full AI Analyst Report?
ESTA Stock Chart & Stats
$67.08
-$0.07(-0.15%)
At close: 4:00 PM EST
$67.08
-$0.07(-0.15%)
Day’s Range― - ―
52-Week Range$33.35 - $83.31
Previous CloseN/A
Volume125.18K
Average Volume (3M)510.67K
Market Cap
$2.07B
Enterprise Value$2.28B
Total Cash (Recent Filing)$68.10M
Total Debt (Recent Filing)$263.96M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 11, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding29,430,390
10 Day Avg. Volume576,705
30 Day Avg. Volume510,665
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)91.68
Price to Sales (P/S)10.23
P/FCF Ratio-37.92
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue9.92
Enterprise Value/Gross Profit14.15
Enterprise Value/Ebitda-111.86
Forecast
1Y Price Target
$89.50Price Target Upside33.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.15
Revenue Forecast (FY)$267.19M
Bulls Say, Bears Say
Bulls Say
U.S. Commercial MomentumRapid U.S. adoption materially expands the company’s addressable market and diversifies revenue away from slower OUS regions. Sustained U.S. traction accelerates surgeon certification, order frequency and brand pull, creating durable growth runway and higher-volume channels that support long-term scale.
High & Expanding Gross MarginsMargins near 70% indicate strong unit economics from product design, manufacturing and pricing power. Durable high gross margins provide structural capacity to absorb commercial investments, fund R&D and drive eventual operating leverage as revenue scales toward profitable free cash flow.
Product Differentiation & Clinical SafetyBest-in-class safety and clinical outcomes create a durable competitive advantage in surgeon and patient preference, supporting premium pricing, lower warranty/claims costs, and faster word-of-mouth adoption. Clinical credibility raises barriers for competitors and supports long-term market share gains.
Bears Say
Persistent Cash BurnSustained negative operating cash flow forces reliance on financing or near-term improvement in cash conversion. This elevates refinancing, covenant and dilution risk, and means growth must translate to rapid conversion to free cash flow to avoid recurring capital raises that dilute shareholders or constrain strategy.
High Operating SpendVery high SG&A as a share of revenue indicates scalability risk: until revenues scale materially, expense intensity will pressure margins. If U.S. adoption or conversion lags, elevated spend could delay or reverse profitability improvements and increase dependence on external funding.
Levered Financing With PIK OptionalityPIK interest and higher-stated rates defer cash payments but compound future interest-bearing obligations, tightening leverage if growth or cash conversion slows. Covenant constraints and accrual mechanics reduce financial flexibility and raise execution risk over multiple quarters if performance deviates.
Establishment Labs Holdings News
ESTA FAQ
What was Establishment Labs Holdings Inc’s price range in the past 12 months?
Establishment Labs Holdings Inc lowest stock price was $33.35 and its highest was $83.31 in the past 12 months.
What is Establishment Labs Holdings Inc’s market cap?
Establishment Labs Holdings Inc’s market cap is $2.07B.
When is Establishment Labs Holdings Inc’s upcoming earnings report date?
Establishment Labs Holdings Inc’s upcoming earnings report date is Aug 11, 2026 which is in 67 days.
How were Establishment Labs Holdings Inc’s earnings last quarter?
Establishment Labs Holdings Inc released its earnings results on May 06, 2026. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.355 by -$0.095.
Is Establishment Labs Holdings Inc overvalued?
According to Wall Street analysts Establishment Labs Holdings Inc’s price is currently Undervalued.
Does Establishment Labs Holdings Inc pay dividends?
Establishment Labs Holdings Inc does not currently pay dividends.
What is Establishment Labs Holdings Inc’s EPS estimate?
Establishment Labs Holdings Inc’s EPS estimate is -0.34.
How many shares outstanding does Establishment Labs Holdings Inc have?
Establishment Labs Holdings Inc has 29,430,390 shares outstanding.
What happened to Establishment Labs Holdings Inc’s price movement after its last earnings report?
Establishment Labs Holdings Inc reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.355. Following the earnings report the stock price went up 5.001%.
Which hedge fund is a major shareholder of Establishment Labs Holdings Inc?
Currently, no hedge funds are holding shares in ESTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Establishment Labs Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.50 (33.42% Upside)
$89.50 (33.42% Upside)
Blogger Sentiment
Bullish
ESTA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 7.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.47%
12-Months-Change
Fundamentals
Return on Equity
-225.86%
Trailing 12-Months
Asset Growth
5.30%
Trailing 12-Months
Company Description
Establishment Labs Holdings Inc
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
ESTA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and commercial momentum led by a rapid U.S. launch, 45% YoY revenue growth in Q1, improving gross margin (70.7%) and a return to positive adjusted EBITDA. Key product innovations (minimally invasive platform) are driving adoption, surgeon and patient demand, and management raised full-year revenue guidance. Offsetting factors include elevated operating expenses, near-term cash usage and increased debt with PIK mechanics, plus some supply and geopolitical uncertainties. Overall, the positives around revenue acceleration, margin expansion, product differentiation and pathway to cash-flow positivity materially outweigh the risks discussed.View all ESTA earnings summariesESTA Stock 12 Month Forecast
Average Price Target
$89.50
▲(33.42% Upside)
Technical Analysis
Ownership Overview
17.96% Insiders
6.12% Mutual Funds
63.12% Other Institutional Investors
11.52% Public Companies and
Individual Investors